RealFeedApp beta

Pfizer pays Starna $330 million upfront

Pfizer paid $330 million upfront and gained exclusive rights to three preclinical programs treating autoimmune diseases using in vivo cell therapy.

Field
industry news
What they did
Pfizer signed an agreement with Starna Therapeutics to gain exclusive rights to three preclinical programs for treating autoimmune diseases using 'in vivo' cell therapy.
Why it matters
Pfizer will pay $330 million upfront and receive additional payments for reaching development and commercial milestones, expanding their pipeline.
#car-t#in vivo#cell therapy#pfizer#starna therapeutics

Read the original →